Navigation Links
Virtual Colonoscopies Show Value for Some Patients, But Polyps Will Be Missed

ECRI Institute(R) Evidence Report Compares Effectiveness of CT Colonography to Colonoscopy

PLYMOUTH MEETING, Pa., March 12 /PRNewswire-USNewswire/ -- The value of CT colonography, also called virtual colonoscopy, is under debate as Medicare considers halting coverage of these procedures as a diagnostic method for detecting colorectal cancer and precancerous growths. Research findings from meta-analyses performed by ECRI Institute suggest that CT colonography appears most promising for screening asymptomatic, average-risk patients; however, it will miss some important polyps and cancer that would have been detected by colonoscopy. For asymptomatic high-risk patients and symptomatic patients, the percentage of patients correctly identified as having colorectal polyps or cancer may be too low to be useful.

"While some patients may prefer CT colonography, it may not be the best choice for everyone," Meredith Noble, an ECRI Institute researcher, notes. "Although CT colonography may be a useful alternative for patients with contraindications to colonoscopy or for whom colonoscopy cannot be completed, it may be less useful for patients who will inevitably require a subsequent therapeutic colonoscopy."

ECRI Institute (, an independent, nonprofit organization that researches the best approaches to improving patient care, analyzed recent studies on the comparative effectiveness of CT colonography to traditional colonoscopy. Researchers focused on five key issues: 1) diagnostic performance for detecting clinically important polyps or cancer, 2) impact on long-term clinical outcomes, 3) patient preferences, 4) adverse events, and 5) impact of offering CT colonography on patient compliance with CRC screening recommendations. Researchers reviewed 17 publications of studies that reported on 7,460 patients.

According to ECRI Institute's research, CT colonography correctly identified between 86% and 95% of asymptomatic, average-risk patients with large polyps and cancers that were identified by colonoscopy and between 76% and 95% of symptomatic patients with large polyps and cancers. No firm conclusions could be drawn regarding the proportion of asymptomatic high-risk patients with important polyps that would be identified by CT colonography, but the studies ECRI Institute analyzed reported that CT colonography identified no more than 85% of these patients.

Long-term follow-up data is not available to compare the clinical outcomes (including side effects) of patients diagnosed or screened with CT colonography to the outcomes of patients who underwent colonoscopy. Information is also insufficient to gauge the possible long-term effects of repeat radiation exposure from CT colonography at the regular recommended intervals for colorectal cancer screening.

Nine studies ECRI Institute analyzed suggest that the majority of patients who underwent both CT colonography and colonoscopy for screening and diagnosis preferred CT colonography. However, a lack of evidence prevented ECRI Institute from determining whether offering CT colonography increases overall patient participation in colorectal cancer screening.

Both procedures involve the same patient bowel preparations. However, no sedative is administered for CT colonography. CT colonography involves taking a series of scans in a 15-20 minute procedure. Computer software translates the scans into a readable format. Because CT can only take pictures, suspicious polyps cannot be removed during this procedure. If suspicious polyps are identified, a subsequent colonoscopy should be scheduled, and if a facility cannot do it the same day as the colonography was performed, the patient must repeat the bowel preparation procedure for the follow-up colonoscopy.

For more information on ECRI Institute's Evidence Report, "Computed Tomographic (CT) Colonography for Colorectal Cancer Screening and Diagnosis," included in membership to ECRI Institute's Health Technology Assessment Information Service(TM), or for information about other comparative effectiveness reviews and health technology assessment services, e-mail, call (610) 825-6000, ext. 5060, or write to us at ECRI Institute, 5200 Butler Pike, Plymouth Meeting, PA, USA, 19462.

About ECRI Institute

ECRI Institute, a nonprofit organization, dedicates itself to bringing the discipline of applied scientific research to healthcare to uncover the best approaches to improving patient care. As pioneers in this science for 40 years, ECRI Institute marries experience and independence with the objectivity of evidence-based research. ECRI Institute is designated a Collaborating Center of the World Health Organization and an Evidence-based Practice Center by the U.S. Agency for Healthcare Research and Quality.

Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. VirtualScopics Quantitative Imaging Provides Primary Endpoint in Cartilage Repair Pivotal Clinical Trial
2. Video: Large, Multi-Center Trial Demonstrates Comparable Accuracy for Virtual Colonoscopy and Standard Colonoscopy
3. MultiVu Video Feed: Major Trial Demonstrates Comparable Accuracy of Virtual Colonoscopy and Standard Colonoscopy
4. iCAD Initiates Clinical Study of Its Virtual Colonoscopy CAD in Partnership with ACR Image Metrix
5. ACR Supports American Cancer Society Inclusion of CT Colonography (Virtual Colonoscopy) as Recommended Screening Tool for Colorectal Cancer in New Screening Guidelines
6. iCAD Announces Partnership for Initiating Clinical Testing of Its Virtual Colonoscopy CAD Product
7. ACRIN Study Endorses Virtual Colonoscopy - Validation for Colon CAD Software Maker Medicsight plc
8. Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A
9. University of Miami Team Confirms Value of Monitoring Cell-Mediated Immunity Pre- and Post-Transplant in Management of Kidney Transplant Recipients
10. Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions
11. BRAVE-3 Questions Value of Abciximab in PCI for Heart Attack
Post Your Comments:
(Date:6/24/2016)... , June 24, 2016  Collagen Matrix, ... design, development and manufacturing of collagen and mineral ... announced today that Bill Messer has ... Marketing to further leverage the growing portfolio of ... devices. Bill joins the Collagen Matrix ...
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... and Markets has announced the addition of the ... their offering. ... products and provides an updated review, including its applications ... covering the total market, which includes three main industries: ...
(Date:6/24/2016)... June 24, 2016 Dehaier Medical Systems Ltd. ... which develops, markets and sells medical devices and wearable ... signed a strategic cooperation agreement with Hongyuan Supply Chain ... Chain") on June 20, 2016, to develop Dehaier,s new ... cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s sales ...
Breaking Medicine Technology:
(Date:6/24/2016)... Rhinebeck, NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of ... of companies that call for a minimum wage raise to $12 an hour by 2020 ... wage. This will restore the lost value of the minimum wage, assure the wage floor ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB ... Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards ... in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative ... has initiated cultivation and processing operations at its production facility, and opened its ... Puradigm is the manufacturer of a complete system of proactive air and surface ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... National recruitment ... a life sciences executive with extensive sequencing and genomics experience, as Vice President of ... position, Ms. Hill will be responsible for leading the sales team in the commercialization ...
(Date:6/24/2016)... Gaithersburg, MD (PRWEB) , ... June 24, 2016 ... ... and protocols for human induced pluripotent stem (iPS) cells and other difficult to ... PluriQ™ G9™ Cloning Medium. The PluriQ™ G9™ Gene Editing System is ...
Breaking Medicine News(10 mins):